Sanofi is rumored to have a $50 billion budget for mergers and acquisitions and is taking a look at U.S.-based biotech companies, including South San Francisco-based Principia Biopharma.

Rumors that Celgene Corporation is in talks to acquire Juno Therapeutics caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.

AstraZeneca’s combination of two injectable immunotherapy drugs failed to help patients as hoped in a closely watched advanced lung cancer trial, triggering the biggest ever daily fall in its shares.

July 21, 2017 By Alex Keown, BioSpace.com Breaking News Staff LONDON – After a period of uncertainty, AstraZeneca (AZN) Chief Executive Officer Pascal Soriot finally broke his silence to squelch rumors he was departing the company and urged his employees to remain focused on the company’s goals. In an internal memo sent earlier this week […]

After months of speculation on who Pfizer Inc. (PFE) will attempt to buy are now officially over — sort of. It has been confirmed that Pfizer Inc. and Allergan Plc (AGN), according to the Wall Street Journal, are discussing a potential merger. The two companies have declined to comment.   Analysts have been speculating on […]

Ever since Pfizer Inc. (PFE)’s $119 billion bid for UK-based AstraZeneca PLC (AZN) collapsed in May 2014, analysts have speculated on who Pfizer might buy. For several months now, heating up at the moment, those rumors have been that Pfizer might take a shot at UK-based GlaxoSmithKline (GSK).   The speculation over a Pfizer-GSK deal […]